KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Sparsentan Versus Irbesartan in Pediatric Patients With FSGS.

Michelle N Rheault, Katherine M Dell, Kenneth V Lieberman, Kevin Meyers, Ana Paredes, Edward Murphy, Jula K Inrig, Radko Komers, Howard Trachtman

Kidney Int Rep 11(7) 106566

PMID42210914
PMCIDPMC13213750
DOI10.1016/j.ekir.2026.106566
发表日期2026-05-29
摘要

摘要

INTRODUCTION: Sparsentan, a nonimmunosuppressive dual endothelin angiotensin receptor antagonist, led to rapid and sustained proteinuria reductions versus maximum labeled dose irbesartan in patients with focal segmental glomerulosclerosis (FSGS) in the phase 3 DUPLEX trial (NCT03493685). Here, we describe the efficacy and safety of sparsentan in the pediatric patients enrolled in DUPLEX. METHODS: DUPLEX was a 108-week randomized trial of sparsentan versus irbesartan (active control) in patients with FSGS (excluding known secondary causes). A post hoc analysis assessed efficacy and safety in the pediatric subgroup (8 to < 18 years). Outcomes included proteinuria (urine protein-to-creatinine ratio [UPCR]) changes from baseline; rates of complete remission (CR) of proteinuria (UPCR of < 0.3 g/g); FSGS partial remission end point (UPCR of ≤ 1.5 g/g and > 40% reduction from baseline); UPCR of < 0.5, < 0.7, or < 1.0 g/g at any time; rates of kidney failure; and safety. RESULTS: Thirty-five pediatric patients received sparsentan (n = 16) or irbesartan (n = 19). UPCR reductions were observed as early as week 6 and sustained through 108 weeks (mean reduction at 108 weeks: sparsentan, 39.5% vs. irbesartan, 24.9%). More patients in the sparsentan arm than the irbesartan arm achieved low proteinuria thresholds, including CR (12.5% vs. 5.3%) and the FSGS partial remission end point (56.3% vs. 36.8%). Sparsentan and irbesartan had similar safety profiles, with comparable incidence and severity of adverse events. CONCLUSION: In this post hoc analysis of pediatric patients with FSGS, sparsentan was generally well tolerated and clinically meaningful reductions in proteinuria were observed, consistent with the overall DUPLEX population.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。